© 2002 European Society of Cardiology
Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin
a Division of Cardiovascular Surgery, Department of Surgery, Maimomides Medical Center, Administration Building, Rm D, Department of Surgery 4802 10th Ave, Brooklyn, NY 11219, USA
b Division of Cardiothoracic Surgery, Department of Surgery, State University of New York-Health Science Center (SUNY-HSC) at Brooklyn Brooklyn, NY, USA
* Corresponding author: Tel.: +1-718-283-7686; fax: +1-718-283-7392. E-mail address: mishavayn{at}aol.com
 |
Abstract |
|---|
Aims: The purpose of this study was to determine that the administration of an angiotensin converting enzyme (ACE) inhibitor enalapril would confer protection against doxorubicin-induced experimental heart failure, and attenuate the development of left ventricular dysfunction.
Methods: Seventeen dogs were chronically instrumented with an intracoronary catheter and received doxorubicin weekly for 4 weeks. Animals were assigned to two groups: group 1: untreated heart failure; and group 2: simultaneous enalapril administration (5 mg twice a week). Hemodynamic data were obtained at week 0 and 12. Echocardiography was performed weekly.
Results: Survival improved with simultaneous enalapril administration (36% in group 1 vs. 100% in group 2, P=0.04). The increase in the left ventricular end-diastolic pressure was significantly reduced at week 12 (17±1 mmHg in group 1 vs. 9±1 mmHg in group 2, P=0.0042). The fall in left ventricular stroke work index was significantly prevented (52% in group 1 vs. 21% in group 2, P=0.006). The increase in right ventricular end-diastolic diameter was significantly reduced by enalapril prophylaxis.
Conclusion: Simultaneous treatment with enalapril was beneficial in the prevention of doxorubicin-induced cardiomyopathy.
Key Words: Heart failure • Cardiomyopathy • Dog • ACE inhibitors • Ventricular function
Received March 29, 2001; Revised February 7, 2002; Accepted April 25, 2002
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Cardinale, A. Colombo, G. Lamantia, N. Colombo, M. Civelli, G. De Giacomi, M. Rubino, F. Veglia, C. Fiorentini, and C. M. Cipolla Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic Therapy J. Am. Coll. Cardiol., January 19, 2010; 55(3): 213 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Riad, S. Bien, D. Westermann, P. M. Becher, K. Loya, U. Landmesser, H. K. Kroemer, H. P. Schultheiss, and C. Tschope Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice Cancer Res., January 15, 2009; 69(2): 695 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Riad, S. Bien, M. Gratz, F. Escher, M. M. Heimesaat, S. Bereswill, T. Krieg, S. B. Felix, H. P. Schultheiss, H. K. Kroemer, et al. Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice Eur J Heart Fail, March 1, 2008; 10(3): 233 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. W. Jones, M. J. Haykowsky, J. J. Swartz, P. S. Douglas, and J. R. Mackey Early Breast Cancer Therapy and Cardiovascular Injury J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1435 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cardinale, A. Colombo, M. T. Sandri, G. Lamantia, N. Colombo, M. Civelli, G. Martinelli, F. Veglia, C. Fiorentini, and C. M. Cipolla Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition Circulation, December 5, 2006; 114(23): 2474 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Simunek, I. Klimtova, J. Kaplanova, Y. Mazurova, M. Adamcova, M. Sterba, R. Hrdina, and V. Gersl Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents Eur J Heart Fail, June 1, 2004; 6(4): 377 - 387. [Abstract] [Full Text] [PDF]
|
|